Role of tumor suppressor genes in the cancer-associated reprogramming of human induced pluripotent stem cells

Stem Cell Research and Therapy

Volumn 5, Issue 2, 2014, Pages

  Lin, Ying Chu ^a,b   Murayama, Yoshinobu ^c   Hashimoto, Koichiro ^d   Nakamura, Yukio ^e   Lin, Chang Shin ^f,g   Yokoyama, Kazunari K ^f   Saito, Shigeo ^h,i  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NIHON UNIVERSITY   (Japan)

^d TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

^e RIKEN BIORESOURCE CENTER   (Japan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^h Saito Laboratory of Cell Technology   (Japan)

ⁱ TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; REACTIVE OXYGEN METABOLITE;

CANCER MODEL; CANCER RISK; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL AGING; CELL CYCLE ARREST; DNA DAMAGE; EPIGENETICS; GENE ACTIVATION; GENE FUNCTION; GENE INACTIVATION; GENOME IMPRINTING; HUMAN; METABOLIC STRESS; NONHUMAN; OXIDATIVE STRESS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; NUCLEAR REPROGRAMMING; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; GENES, TUMOR SUPPRESSOR; HUMANS; INDUCED PLURIPOTENT STEM CELLS;

EID: 84899703979     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt447     Document Type: Review

References (96)

1. Establishment in culture of pluripotential cells from mouse embryos. MJ Evans, MH Kaufman, Nature 1981 292 154 156 10.1038/292154a0 7242681
2. Viable offspring derived from fetal and adult mammalian cells. I Wilmut, AE Schnieke, J McWhir, AJ Kind, KH Campbell, Nature 1997 385 810 813 10.1038/385810a0 9039911
3. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. K Takahashi, S Yamanaka, Cell 2006 126 663 676 10.1016/j.cell.2006.07.024 16904174
4. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. D Huangfu, R Maehr, W Guo, A Eijkelenboom, M Snitow, AE Chen, DA Melton, Nat Biotechnol 2008 26 795 797 10.1038/nbt1418 18568017
5. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. JK Ichida, J Blanchard, K Lam, EY Son, JE Chung, D Egli, KM Loh, AC Carter, FP Di Giorgio, K Koszka, D Huangfu, H Akutsu, DR Liu, LL Rubin, K Eggan, Cell Stem Cell 2009 5 491 503 10.1016/j.stem.2009.09. 012 19818703
6. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. W Li, W Wei, S Zhu, J Zhu, Y Shi, T Lin, E Hao, A Hayek, H Deng, S Ding, Cell Stem Cell 2009 4 16 19 10.1016/j.stem.2008.11.014 19097958
7. Core transcriptional regulatory circuitry in human embryonic stem cells. LA Boyer, TI Lee, MF Cole, SE Johnstone, SS Levine, JP Zucker, MG Guenther, RM Kumar, HL Murray, RG Jenner, DK Gifford, DA Melton, R Jaenisch, RA Young, Cell 2005 122 947 956 10.1016/j.cell.2005.08.020 16153702
8. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. K Hochedlinger, Y Yamada, C Beard, R Jaenisch, Cell 2005 121 465 477 10.1016/j.cell.2005.02.018 15882627
9. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. YH Loh, Q Wu, JL Chew, VB Vega, W Zhang, X Chen, G Bourque, J George, B Leong, J Liu, KY Wong, KW Sung, CW Lee, XD Zhao, KP Chiu, L Lipovich, VA Kuznetsov, P Robson, LW Stanton, CL Wei, Y Ruan, B Lim, HH Ng, Nat Genet 2006 38 431 440 10.1038/ng1760 16518401
10. An Oct4-centered protein interaction network in embryonic stem cells. DL van den Berg, T Snoek, NP Mullin, A Yates, K Bezstarosti, J Demmers, I Chambers, RA Poot, Cell Stem Cell 2010 6 369 381 10.1016/j.stem.2010.02.014 20362541
11. Embryonic stem cell self-renewal pathways converge on the transcription factor Tfcp2l1. S Ye, P Li, C Tong, QL Ying, EMBO J 2013 32 2548 2560 10.1038/emboj.2013.175 23942238
12. Identification of the missing pluripotency mediator downstream of leukaemia inhibitory factor. G Martello, P Bertone, A Smith, EMBO J 2013 32 2561 2574 10.1038/emboj.2013.177 23942233
13. Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. MF Kielman, M Rindapaa, C Gaspar, N van Poppel, C Breukel, S van Leeuwen, MM Taketo, S Roberts, R Smits, R Fodde, Nat Genet 2002 32 594 605 10.1038/ng1045 12426568
14. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. N Sato, L Meijer, L Skaltsounis, P Greengard, AH Brivanlou, Nat Med 2004 10 55 63 10.1038/nm979 14702635
15. Synergistic action of Wnt and LIF in maintaining pluripotency of mouse ES cells. K Ogawa, R Nishinakamura, Y Iwamatsu, D Shimosato, H Niwa, Biochem Biophys Res Commun 2006 343 159 166 10.1016/j.bbrc.2006.02.127 16530170
16. Beta-catenin up-regulates Nanog expression through interaction with Oct-3/4 in embryonic stem cells. Y Takao, T Yokota, H Koide, Biochem Biophys Res Commun 2007 353 699 705 10.1016/j.bbrc.2006.12.072 17196549
17. Wnt signaling promotes reprogramming of somatic cells to pluripotency. A Marson, R Foreman, B Chevalier, S Bilodeau, M Kahn, RA Young, R Jaenisch, Cell Stem Cell 2008 3 132 135 10.1016/j.stem.2008.06.019 18682236
18. Beta-catenin signaling is required for neural differentiation of embryonic stem cells. JJ Otero, W Fu, L Kan, AE Cuadra, JA Kessler, Development 2004 131 3545 3557 10.1242/dev.01218 15262888
19. Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm. RC Lindsley, JG Gill, M Kyba, TL Murphy, KM Murphy, Development 2006 133 3787 3796 10.1242/dev.02551 16943279
20. Oct-3/4 regulates stem cell identity and cell fate decisions by modulating Wnt/beta-catenin signalling. M Abu-Remaileh, A Gerson, M Farago, G Nathan, I Alkalay, S Zins Rousso, M Gur, A Fainsod, Y Bergman, EMBO J 2010 29 3236 3248 10.1038/emboj.2010.200 20736927
21. Myc activates telomerase. J Wang, LY Xie, S Allan, D Beach, GJ Hannon, Genes Dev 1998 12 1769 1774 10.1101/gad.12.12.1769 9637678
22. The stem cell identity of testicular cancer. AT Clark, Stem Cell Rev 2007 3 49 59 10.1007/s12015-007-0002-x 17873381
23. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. Y Chen, L Shi, L Zhang, R Li, J Liang, W Yu, L Sun, X Yang, Y Wang, Y Zhang, Y Shang, J Biol Chem 2008 283 17969 17978 10.1074/jbc.M802917200 18456656
24. Stem cells: the promises and perils of p53. V Krizhanovsky, SW Lowe, Nature 2009 460 1085 1086 10.1038/4601085a 19713919
25. In vitro generation of human cells with cancer stem cell properties. P Scaffidi, T Misteli, Nat Cell Biol 2011 13 1051 1061 10.1038/ncb2308 21857669
26. p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome. BT Spike, GM Wahl, Genes Cancer 2011 2 404 419 10.1177/1947601911410224 21779509
27. Cancer-susceptibility genes. Gatekeepers and caretakers. KW Kinzler, B Vogelstein, Nature 1997 386 761 763 10.1038/386761a0 9126728
28. Mechanisms of stem cell self-renewal. S He, D Nakada, SJ Morrison, Annu Rev Cell Dev Biol 2009 25 377 406 10.1146/annurev.cellbio.042308.113248 19575646
29. p16INK4a induces an age-dependent decline in islet regenerative potential. J Krishnamurthy, MR Ramsey, KL Ligon, C Torrice, A Koh, S Bonner-Weir, NE Sharpless, Nature 2006 443 453 457 10.1038/nature05092 16957737
30. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. V Janzen, R Forkert, HE Fleming, Y Saito, MT Waring, DM Dombkowski, T Cheng, RA DePinho, NE Sharpless, DT Scadden, Nature 2006 443 421 426 16957735
31. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. AV Molofsky, R Pardal, T Iwashita, IK Park, MF Clarke, SJ Morrison, Nature 2003 425 962 967 10.1038/nature02060 14574365
32. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. JY Lee, D Nakada, OH Yilmaz, Z Tothova, NM Joseph, MS Lim, DG Gilliland, SJ Morrison, Cell Stem Cell 2010 7 593 605 10.1016/j.stem.2010.09.015 21040901
33. p53 mutant mice that display early ageing-associated phenotypes. SD Tyner, S Venkatachalam, J Choi, S Jones, N Ghebranious, H Igelmann, X Lu, G Soron, B Cooper, C Brayton, SH Park, T Thompson, G Karsenty, A Bradley, LA Donehower, Nature 2002 415 45 53 10.1038/415045a 11780111
34. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. M Dumble, L Moore, SM Chambers, H Geiger, G Van Zant, MA Goodell, LA Donehower, Blood 2007 109 1736 1742 10.1182/blood-2006-03-010413 17032926
35. Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. HS Gannon, LA Donehower, S Lyle, SN Jones, Dev Biol 2011 353 1 9 10.1016/j.ydbio.2011.02.007 21334322
36. Variation in the human TP53 gene affects old age survival and cancer mortality. D van Heemst, SP Mooijaart, M Beekman, J Schreuder, AJ de Craen, BW Brandt, PE Slagboom, RG Westendorp, Long Life study group, Exp Gerontol 2005 40 11 15 10.1016/j.exger.2004.10.001 15732191
37. Removing all obstacles: a critical role for p53 in promoting tissue renewal. DW Schoppy, Y Ruzankina, EJ Brown, Cell Cycle 2010 9 1313 1319 20234190
38. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Y Ruzankina, C Pinzon-Guzman, A Asare, T Ong, L Pontano, G Cotsarelis, VP Zediak, M Velez, A Bhandoola, EJ Brown, Cell Stem Cell 2007 1 113 126 10.1016/j.stem.2007.03.002 18371340
39. p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Y Begus-Nahrmann, A Lechel, AC Obenauf, K Nalapareddy, E Peit, E Hoffmann, F Schlaudraff, B Liss, P Schirmacher, H Kestler, E Danenberg, N Barker, H Clevers, MR Speicher, KL Rudolph, Nat Genet 2009 41 1138 1143 10.1038/ng.426 19718028
40. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. H Zheng, H Ying, H Yan, AC Kimmelman, DJ Hiller, AJ Chen, SR Perry, G Tonon, GC Chu, Z Ding, JM Stommel, KL Dunn, R Wiedemeyer, MJ You, C Brennan, YA Wang, KL Ligon, WH Wong, L Chin, RA DePinho, Nature 2008 455 1129 1133 10.1038/nature07443 18948956
41. Selective activation of p53-mediated tumour suppression in high-grade tumours. MR Junttila, AN Karnezis, D Garcia, F Madriles, RM Kortlever, F Rostker, L Brown Swigart, DM Pham, Y Seo, GI Evan, CP Martins, Nature 2010 468 567 571 10.1038/nature09526 21107427
42. Stage-specific sensitivity to p53 restoration during lung cancer progression. DM Feldser, KK Kostova, MM Winslow, SE Taylor, C Cashman, CA Whittaker, FJ Sanchez-Rivera, R Resnick, R Bronson, MT Hemann, T Jacks, Nature 2010 468 572 575 10.1038/nature09535 21107428
43. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. J Utikal, JM Polo, M Stadtfeld, N Maherali, W Kulalert, RM Walsh, A Khalil, JG Rheinwald, K Hochedlinger, Nature 2009 460 1145 1148 10.1038/nature08285 19668190
44. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. R Sarig, N Rivlin, R Brosh, C Bornstein, I Kamer, O Ezra, A Molchadsky, N Goldfinger, O Brenner, V Rotter, J Exp Med 2010 207 2127 2140 10.1084/jem.20100797 20696700
45. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. T Kawamura, J Suzuki, YV Wang, S Menendez, LB Morera, A Raya, GM Wahl, JC Izpisua Belmonte, Nature 2009 460 1140 1144 10.1038/nature08311 19668186
46. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. H Hong, K Takahashi, T Ichisaka, T Aoi, O Kanagawa, M Nakagawa, K Okita, S Yamanaka, Nature 2009 460 1132 1135 10.1038/nature08235 19668191
47. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. RM Marion, K Strati, H Li, M Murga, R Blanco, S Ortega, O Fernandez-Capetillo, M Serrano, MA Blasco, Nature 2009 460 1149 1153 10.1038/nature08287 19668189
48. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. DC Wallace, Annu Rev Genet 2005 39 359 407 10.1146/annurev.genet.39.110304.095751 16285865
49. Progress in understanding reprogramming to the induced pluripotent state. K Plath, WE Lowry, Nat Rev Genet 2011 12 253 265 10.1038/nrg2955 21415849
50. Evolution of induced pluripotent stem cell technology. H Zhou, S Ding, Curr Opin Hematol 2010 17 276 280 10.1097/MOH.0b013e328339f2ee 20442654
51. Regulation of ROS in transmissible gastroenteritis virus-activated apoptotic signaling. L Ding, X Zhao, Y Huang, Q Du, F Dong, H Zhang, X Song, W Zhang, D Tong, Biochem Biophys Res Commun 2013 442 33 37 10.1016/j.bbrc.2013.10. 164 24225120
52. Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells. C Ono, A Ninomiya, S Yamamoto, T Abe, X Wen, T Fukuhara, M Sasai, M Yamamoto, T Saitoh, T Satoh, T Kawai, KJ Ishii, S Akira, T Okamoto, Y Matsuura, J Virol 2014 88 2157 2167 10.1128/JVI.03055-13 24335288
53. The Ink4/Arf locus is a barrier for iPS cell reprogramming. H Li, M Collado, A Villasante, K Strati, S Ortega, M Canamero, MA Blasco, M Serrano, Nature 2009 460 1136 1139 10.1038/nature08290 19668188
54. Hypoxia enhances the generation of induced pluripotent stem cells. Y Yoshida, K Takahashi, K Okita, T Ichisaka, S Yamanaka, Cell Stem Cell 2009 5 237 241 10.1016/j.stem.2009.08.001 19716359
55. Molecular insights into reprogramming-initiation events mediated by the OSKM gene regulatory network. N Mah, Y Wang, MC Liao, A Prigione, J Jozefczuk, B Lichtner, K Wolfrum, M Haltmeier, M Flottmann, M Schaefer, A Hahn, R Mrowka, E Klipp, MA Andrade-Navarro, J Adjaye, PloS One 2011 6 24351 10.1371/journal.pone. 0024351 21909390
56. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. MA Esteban, T Wang, B Qin, J Yang, D Qin, J Cai, W Li, Z Weng, J Chen, S Ni, K Chen, Y Li, X Liu, J Xu, S Zhang, F Li, W He, K Labuda, Y Song, A Peterbauer, S Wolbank, H Redl, M Zhong, D Cai, L Zeng, D Pei, Cell Stem Cell 2010 6 71 79 10.1016/j.stem.2009.12.001 20036631
57. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. T Wang, K Chen, X Zeng, J Yang, Y Wu, X Shi, B Qin, L Zeng, MA Esteban, G Pan, D Pei, Cell Stem Cell 2011 9 575 587 10.1016/j.stem.2011.10.005 22100412
58. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. T Chen, L Shen, J Yu, H Wan, A Guo, J Chen, Y Long, J Zhao, G Pei, Aging cell 2011 10 908 911 10.1111/j.1474-9726. 2011.00722.x 21615676
59. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. JA Menendez, L Vellon, C Oliveras-Ferraros, S Cufi, A Vazquez-Martin, Cell Cycle 2011 10 3658 3677 10.4161/cc.10.21.18128 22052357
60. Senescence impairs successful reprogramming to pluripotent stem cells. A Banito, ST Rashid, JC Acosta, S Li, CF Pereira, I Geti, S Pinho, JC Silva, V Azuara, M Walsh, L Vallier, J Gil, Genes Dev 2009 23 2134 2139 10.1101/gad.1811609 19696146
61. Cellular senescence in cancer and aging. M Collado, MA Blasco, M Serrano, Cell 2007 130 223 233 10.1016/j.cell.2007.07.003 17662938
62. Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2. CF Pereira, R Terranova, NK Ryan, J Santos, KJ Morris, W Cui, M Merkenschlager, AG Fisher, PLoS Genet 2008 4 1000170 10.1371/journal.pgen.1000170 18773085
63. Dissecting direct reprogramming through integrative genomic analysis. TS Mikkelsen, J Hanna, X Zhang, M Ku, M Wernig, P Schorderet, BE Bernstein, R Jaenisch, ES Lander, A Meissner, Nature 2008 454 49 55 10.1038/nature07056 18509334
64. Role of the murine reprogramming factors in the induction of pluripotency. R Sridharan, J Tchieu, MJ Mason, R Yachechko, E Kuoy, S Horvath, Q Zhou, K Plath, Cell 2009 136 364 377 10.1016/j.cell.2009.01.001 19167336
65. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. A Molchadsky, N Rivlin, R Brosh, V Rotter, R Sarig, Carcinogenesis 2010 31 1501 1508 10.1093/carcin/bgq101 20504879
66. Promotion of reprogramming to ground state pluripotency by signal inhibition. J Silva, O Barrandon, J Nichols, J Kawaguchi, TW Theunissen, A Smith, PLoS Biol 2008 6 253 10.1371/journal.pbio.0060253 18942890
67. Strategies and new developments in the generation of patient-specific pluripotent stem cells. S Yamanaka, Cell Stem Cell 2007 1 39 49 10.1016/j.stem.2007.05.012 18371333
68. Two supporting factors greatly improve the efficiency of human iPSC generation. Y Zhao, X Yin, H Qin, F Zhu, H Liu, W Yang, Q Zhang, C Xiang, P Hou, Z Song, Y Liu, J Yong, P Zhang, J Cai, M Liu, H Li, Y Li, X Qu, K Cui, W Zhang, T Xiang, Y Wu, Y Zhao, C Liu, C Yu, K Yuan, J Lou, M Ding, H Deng, Cell Stem Cell 2008 3 475 479 10.1016/j.stem.2008.10.002 18983962
69. Induced pluripotent stem cells and senescence: learning the biology to improve the technology. A Banito, J Gil, EMBO Rep 2010 11 353 359 10.1038/embor.2010.47 20379220
70. Cancer. p53, guardian of the genome. DP Lane, Nature 1992 358 15 16 10.1038/358015a0 1614522
71. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. T Lin, C Chao, S Saito, SJ Mazur, ME Murphy, E Appella, Y Xu, Nat Cell Biol 2005 7 165 171 10.1038/ncb1211 15619621
72. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. GB Pierce, WC Speers, Cancer Res 1988 48 1996 2004 2450643
73. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Z Zhao, J Zuber, E Diaz-Flores, L Lintault, SC Kogan, K Shannon, SW Lowe, Genes Dev 2010 24 1389 1402 10.1101/gad.1940710 20595231
74. c-MYC: more than just a matter of life and death. S Pelengaris, M Khan, G Evan, Nat Rev Cancer 2002 2 764 776 10.1038/nrc904 12360279
75. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. J Chen, H Liu, J Liu, J Qi, B Wei, J Yang, H Liang, Y Chen, J Chen, Y Wu, L Guo, J Zhu, X Zhao, T Peng, Y Zhang, S Chen, X Li, D Li, T Wang, D Pei, Nat Genet 2013 45 34 42 23202127
76. Direct cell reprogramming is a stochastic process amenable to acceleration. J Hanna, K Saha, B Pando, J van Zon, CJ Lengner, MP Creyghton, A van Oudenaarden, R Jaenisch, Nature 2009 462 595 601 10.1038/nature08592 19898493
77. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. B Blum, N Benvenisty, Cell Cycle 2009 8 3822 3830 10.4161/cc.8.23.10067 19887907
78. Culture and characterization of human embryonic stem cells. JS Draper, HD Moore, LN Ruban, PJ Gokhale, PW Andrews, Stem Cells Dev 2004 13 325 336 10.1089/scd.2004.13.325 15345125
79. In vitro culture conditions favoring selection of chromosomal abnormalities in human ES cells. MP Imreh, K Gertow, J Cedervall, C Unger, K Holmberg, K Szoke, L Csoregh, G Fried, S Dilber, E Blennow, L Ahrlund-Richter, J Cell Biochem 2006 99 508 516 10.1002/jcb.20897 16622834
80. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. DE Baker, NJ Harrison, E Maltby, K Smith, HD Moore, PJ Shaw, PR Heath, H Holden, PW Andrews, Nat Biotechnol 2007 25 207 215 10.1038/nbt1285 17287758
81. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Y Mayshar, U Ben-David, N Lavon, JC Biancotti, B Yakir, AT Clark, K Plath, WE Lowry, N Benvenisty, Cell Stem Cell 2010 7 521 531 10.1016/j.stem.2010.07.017 20887957
82. Human amnion-derived cells as a reliable source of stem cells. S Saito, YC Lin, Y Murayama, K Hashimoto, KK Yokoyama, Curr Mol Med 2012 12 1340 1349 10.2174/156652412803833625 23016591
83. The tumorigenicity of human embryonic and induced pluripotent stem cells. U Ben-David, N Benvenisty, Nat Rev Cancer 2011 11 268 277 10.1038/nrc3034 21390058
84. Identification of stem cell marker-positive cells by immunofluorescence in term human amnion. T Miki, K Mitamura, MA Ross, DB Stolz, SC Strom, J Reprod Immunol 2007 75 91 96 10.1016/j.jri.2007.03.017 17493686
85. Isolation of amniotic stem cell lines with potential for therapy. P De Coppi, G Bartsch Jr, MM Siddiqui, T Xu, CC Santos, L Perin, G Mostoslavsky, AC Serre, EY Snyder, JJ Yoo, ME Furth, S Soker, A Atala, Nat Biotechnol 2007 25 100 106 10.1038/nbt1274 17206138
86. Amniotic stem cells for cellular cardiomyoplasty: promises and premises. G Walther, J Gekas, OF Bertrand, Catheter Cardiovasc Interv 2009 73 917 924 10.1002/ccd.22016 19455667
87. Human amniotic membrane as an alternative source of stem cells for regenerative medicine. S Diaz-Prado, E Muinos-Lopez, T Hermida-Gomez, C Cicione, ME Rendal-Vazquez, I Fuentes-Boquete, FJ de Toro, FJ Blanco, Differentiation 2011 81 162 171 10.1016/j.diff.2011.01.005 21339039
88. The LARGE principle of cellular reprogramming: lost, acquired and retained gene expression in foreskin and amniotic fluid-derived human iPS cells. K Wolfrum, Y Wang, A Prigione, K Sperling, H Lehrach, J Adjaye, PloS One 2010 5 13703 10.1371/journal.pone.0013703 21060825
89. Progress in the reprogramming of somatic cells. T Ma, M Xie, T Laurent, S Ding, Circ Res 2013 112 562 574 10.1161/CIRCRESAHA.111.249235 23371904
90. Derivation of pluripotent epiblast stem cells from mammalian embryos. IG Brons, LE Smithers, MW Trotter, P Rugg-Gunn, B Sun, C de Sousa Lopes SM, SK Howlett, A Clarkson, L Ahrlund-Richter, RA Pedersen, L Vallier, Nature 2007 448 191 195 10.1038/nature05950 17597762
91. Oct4-induced pluripotency in adult neural stem cells. JB Kim, V Sebastiano, G Wu, MJ Arauzo-Bravo, P Sasse, L Gentile, K Ko, D Ruau, M Ehrich, D van den Boom, J Meyer, K Hubner, C Bernemann, C Ortmeier, M Zenke, BK Fleischmann, H Zaehres, HR Scholer, Cell 2009 136 411 419 10.1016/j.cell.2009. 01.023 19203577
92. Defined factors induce reprogramming of gastrointestinal cancer cells. N Miyoshi, H Ishii, K Nagai, H Hoshino, K Mimori, F Tanaka, H Nagano, M Sekimoto, Y Doki, M Mori, Proc Natl Acad Sci U S A 2010 107 40 45 10.1073/pnas.0912407107 20018687
93. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. SL Lin, DC Chang, S Chang-Lin, CH Lin, DT Wu, DT Chen, SY Ying, RNA 2008 14 2115 2124 10.1261/rna.1162708 18755840
94. Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective. G Liang, Y Zhang, Cell Res 2013 23 49 69 10.1038/cr.2012.175 23247625
95. Somatic coding mutations in human induced pluripotent stem cells. A Gore, Z Li, HL Fung, JE Young, S Agarwal, J Antosiewicz-Bourget, I Canto, A Giorgetti, MA Israel, E Kiskinis, JH Lee, YH Loh, PD Manos, N Montserrat, AD Panopoulos, S Ruiz, ML Wilbert, J Yu, EF Kirkness, JC Izpisua Belmonte, DJ Rossi, JA Thomson, K Eggan, GQ Daley, LS Goldstein, K Zhang, Nature 2011 471 63 67 10.1038/nature09805 21368825
96. Copy number variation and selection during reprogramming to pluripotency. SM Hussein, NN Batada, S Vuoristo, RW Ching, R Autio, E Narva, S Ng, M Sourour, R Hamalainen, C Olsson, K Lundin, M Mikkola, R Trokovic, M Peitz, O Brustle, DP Bazett-Jones, K Alitalo, R Lahesmaa, A Nagy, T Otonkoski, Nature 2011 471 58 62 10.1038/nature09871 21368824